CORA 2025 Abstract Topics
- Advances in autoantibody testing
- Ankylosing spondylitis
- Antiphospholipid syndrome
- Artificial intelligence and autoimmune rheumatological diseases
- Autoimmunity to the autonomic nervous system
- Autoinflammatory diseases
- Biological drugs
- Biomarkers in autoimmune rheumatological conditions
- CAR-T cells and autoimmune rheumatological diseases
- Checkpoint inhibitors induced autoimmunity
- Circulating extracellular vesicles
- Comorbidity in rheumatic and autoimmune diseases
- COVID and autoimmunity
- Environment, epigenetic and genetic
- Etiology, genetics and mechanisms in rheumatic and autoimmune diseases
- Fibromyalgia, chronic pain and pain relief
- Gout
- Idiopathic inflammatory myopathies
- IgG4 related diseases
- IL17, TH17 and cytokines in autoimmunity
- Immunometabolism and autoimmunity
- Infection and autoimmunity
- Innate and adaptive autoimmunity
- Interstitial lung diseases
- IVIG and natural autoantibodies
- Microbiome, probiotic and nutritional factors in autoimmune and rheumatological diseases
- Miscellaneous
- Novel aspects of therapies – biosimilars
- Novel therapeutic targets in rheumatological and autoimmune diseases
- Omics and multi-omics in autoimmune and rheumatological diseases
- Organ involvement in autoimmune rheumatic diseases
- Pathogenetic and protective autoantibodies
- Patient reported outcomes in autoimmune and rheumatological diseases
- Pediatric rheumatology
- Pregnancy and autoimmunity
- Psoriatic arthritis
- Pulmonary arterial hypertension & systemic sclerosis
- Refractory autoimmune diseases
- Registries and cohorts
- Rheumatoid arthritis
- Sjögren’s disease
- Small molecules and inhibitors
- Spondyloarthritis
- Spondyloarthropathies
- Systemic lupus erythematosus – clinical aspects
- Systemic lupus erythematosus – pathogenesis
- Systemic lupus erythematosus – therapies
- Systemic sclerosis – clinical aspects and treatment
- Systemic sclerosis – pathogenesis
- Thyroid autoimmunity
- Vasculitides